Simron Singh

7.6k total citations · 2 hit papers
176 papers, 3.7k citations indexed

About

Simron Singh is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Simron Singh has authored 176 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Oncology, 108 papers in Epidemiology and 76 papers in Neurology. Recurrent topics in Simron Singh's work include Neuroendocrine Tumor Research Advances (104 papers), Lung Cancer Research Studies (97 papers) and Neuroblastoma Research and Treatments (72 papers). Simron Singh is often cited by papers focused on Neuroendocrine Tumor Research Advances (104 papers), Lung Cancer Research Studies (97 papers) and Neuroblastoma Research and Treatments (72 papers). Simron Singh collaborates with scholars based in Canada, United States and Italy. Simron Singh's co-authors include Calvin Law, Julie Hallet, Ning Liu, Refik Saskin, Moisés Cukier, David Chan, Jonathan Strosberg, Eva Segelov, Matthew C. Cheung and Corwyn Rowsell and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Simron Singh

165 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomes

2014 598 citations Julie Hallet, Calvin Law et al. profile →
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

2024 113 citations Simron Singh, Daniel Halperin et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simron Singh Canada	33	2.8k	2.5k	1.7k	430	341	176	3.7k
Eva Segelov Australia	25	1.4k 0.5×	526 0.2×	341 0.2×	419 1.0×	417 1.2×	158	2.4k
E. Aileen Clarke Canada	23	1.3k 0.5×	693 0.3×	215 0.1×	733 1.7×	704 2.1×	37	3.6k
Hassan Errihani Morocco	25	1.3k 0.5×	335 0.1×	116 0.1×	568 1.3×	514 1.5×	306	2.6k
Daneng Li United States	24	1.8k 0.6×	685 0.3×	128 0.1×	690 1.6×	804 2.4×	136	3.5k
Mary Dillhoff United States	34	2.4k 0.8×	854 0.3×	343 0.2×	938 2.2×	1.5k 4.3×	208	4.1k
Susan C. Pitt United States	27	821 0.3×	597 0.2×	333 0.2×	318 0.7×	1.0k 2.9×	106	2.6k
Maureen P. Neary United States	25	717 0.3×	535 0.2×	177 0.1×	538 1.3×	362 1.1×	111	2.4k
Marianne Fonck France	21	1.1k 0.4×	599 0.2×	78 0.0×	728 1.7×	472 1.4×	55	2.8k
Eliza W. Beal United States	31	1.5k 0.5×	692 0.3×	241 0.1×	890 2.1×	1.7k 5.1×	175	3.4k
Tanya M. Wildes United States	34	1.6k 0.6×	201 0.1×	107 0.1×	546 1.3×	375 1.1×	225	3.6k

Countries citing papers authored by Simron Singh

Since Specialization

Citations

This map shows the geographic impact of Simron Singh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simron Singh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simron Singh more than expected).

Fields of papers citing papers by Simron Singh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simron Singh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simron Singh. The network helps show where Simron Singh may publish in the future.

Co-authorship network of co-authors of Simron Singh

This figure shows the co-authorship network connecting the top 25 collaborators of Simron Singh. A scholar is included among the top collaborators of Simron Singh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simron Singh. Simron Singh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Powis, Melanie, Rinku Sutradhar, Simron Singh, et al.. (2024). The Impact of the Pandemic on the Quality of Colorectal and Anal Cancer Care, and 2-Year Clinical Outcomes. Current Oncology. 31(4). 2328–2340. 2 indexed citations

Ng, Sylvia S. W., Hanbo Chen, Simron Singh, et al.. (2024). Tolerability and outcomes of neuroendocrine tumors treated with PRRT and SBRT. SHILAP Revista de lepidopterología. 4(1). e240001–e240001.

Arya, Sumedha, Lee Mozessohn, Inna Y. Gong, et al.. (2024). The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study. Leukemia & lymphoma. 65(5). 629–637. 2 indexed citations

Metser, Ur, et al.. (2024). Dual Somatostatin Receptor/¹⁸F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors. Journal of Nuclear Medicine. 65(10). 1591–1596. 4 indexed citations

Singh, Simron, Daniel Halperin, Sten Myrehaug, et al.. (2024). [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. The Lancet. 403(10446). 2807–2817. 113 indexed citations breakdown →

Bateni, Sarah B., Natalie G. Coburn, Calvin Law, et al.. (2023). Second primary cancers and survival among neuroendocrine tumor patients. Endocrine Related Cancer. 30(8). 3 indexed citations

Gong, Inna Y., Anca Prica, Andrew Calzavara, et al.. (2023). Indolent lymphoma care delivery and outcomes during the COVID‐19 pandemic in Ontario, Canada. British Journal of Haematology. 204(3). 805–814. 2 indexed citations

Hope, Thomas A., Samuel A. Mehr, Michael J. Morris, et al.. (2023). ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA. Endocrine Abstracts. 1 indexed citations

McDonnell, Mark, Catherine Bouvier, Teodora Kolarova, et al.. (2023). Global challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients. Journal of Neuroendocrinology. 35(6). e13310–e13310. 7 indexed citations

10.

Shaunfield, Sara, Kimberly Webster, Karen Kaiser, et al.. (2020). Development of the Functional Assessment of Cancer Therapy-Carcinoid Syndrome Symptom Index. Neuroendocrinology. 111(9). 850–862. 4 indexed citations

11.

Eskander, Antoine, Laura Davis, Haoyu Zhao, et al.. (2019). Symptom burden among head and neck cancer patients in the first year after diagnosis: Association with primary treatment modality. Oral Oncology. 99. 104434–104434. 34 indexed citations

12.

Eskander, Antoine, Monika K. Krzyzanowska, Hadas D. Fischer, et al.. (2018). Emergency department visits and unplanned hospitalizations in the treatment period for head and neck cancer patients treated with curative intent: A population-based analysis. Oral Oncology. 83. 107–114. 23 indexed citations

13.

Cheung, Matthew C., Sarah K. Andersen, Craig C. Earle, Ruth Croxford, & Simron Singh. (2017). Days Spent at Home in the Last 6 Months of Life. a Potential Patient-Determined Quality Indicator for Patients with Hematologic Malignancies at the End of Life. Blood. 130. 281–281. 1 indexed citations

14.

Strosberg, Jonathan, Þorvarður R. Hálfdánarson, Andrew M. Bellizzi, et al.. (2017). The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 46(6). 707–714. 262 indexed citations

15.

Singh, Simron. (2016). ASSOCIATION OF DISEASE PROGRESSION, HEALTH-RELATED QUALITY OF LIFE, AND UTILITY IN PATIENTS WITH ADVANCED, NONFUNCTIONAL, WELL-DIFFERENTIATED GASTROINTESTINAL OR LUNG NEUROENDOCRINE TUMORS IN THE PHASE 3 RADIANT-4 TRIAL.

16.

Yao, James C., Nicola Fazio, Roberto Buzzoni, et al.. (2016). ORAL02.02: Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis. Journal of Thoracic Oncology. 11(11). S253–S253. 2 indexed citations

17.

Yao, James C., Simron Singh, Edward M. Wolin, et al.. (2015). 134O RADIANT-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (NET) of the lung or gastrointestinal (GI) tract. Annals of Oncology. 26. ix40–ix40. 2 indexed citations

18.

Mahar, Alyson, Natalie G. Coburn, & Simron Singh. (2012). A systematic review of surgery for non-curative gastric cancer (Systematic Reviews : Current issues in gastric cancer). Gastric Cancer. 15(1). 2 indexed citations

19.

Gulenchyn, Karen Y., Xiaomei Yao, L. Sylvia, Simron Singh, & Calvin Law. (2012). Radionuclide Therapy in Neuroendocrine Tumours: A Systematic Review. Clinical Oncology. 24(4). 294–308. 44 indexed citations

20.

Singh, Simron, Phyllis Butow, Margaret Charles, & Martin H.N. Tattersall. (2010). Shared decision making in oncology: assessing oncologist behaviour in consultations in which adjuvant therapy is considered after primary surgical treatment. Health Expectations. 13(3). 244–257. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact